| Period | IVF | SPY | Delta |
|---|---|---|---|
| 3M | -63.7% | +11.4% | -75.1% |
| 6M | -80.8% | +8.2% | -89.0% |
| 1Y | -99.1% | +22.9% | -122.0% |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Total revenue | $120K+47.4% | $82K-48.4% | $158K-23.8% | $207K |
| Cost of services | $4.3M+17.5% | $3.6M | — | — |
| Cost of goods sold | $31K+150.6% | $12K | — | — |
| Selling, general and administrative expenses | $7.7M-4.6% | $8.1M+7.7% | $7.5M-25.0% | $10.0M |
| Research and development expenses | $5K | — | $166K-69.5% | $544K |
| Impairment of intangible assets | $1.4M | — | — | — |
| Loss on disposal of fixed assets | $512K | — | — | — |
| Depreciation and amortization | $677K-26.3% | $920K+357.8% | $201K+159.9% | $77K |
| Total operating expenses | $14.1M+7.0% | $13.2M+34.5% | $9.8M-14.5% | $11.4M |
| Loss from operations | -$7.2M-9.2% | -$6.6M+2.1% | -$6.8M+36.3% | -$10.6M |
| Gain from equity method joint ventures | $31K+246.0% | $9K+115.0% | -$60K+69.9% | -$201K |
| Gain on changes in fair value | $5.2M | — | — | — |
| Gain on lease termination | $95K | — | — | — |
| Loss from debt extinguishment | -$2.1M-5174.9% | -$40K+75.2% | -$163K | — |
| Loss on issuance of warrants | -$944K | — | — | — |
| Gain on settlement of liability (Note 18) | $930K | — | — | — |
| Interest expense | -$1.3M-25.8% | -$1.0M-11.8% | -$926K-1457.6% | -$59K |
| Total other income (expenses) | $1.8M+280.1% | -$972K+21.6% | -$1.2M-371.1% | -$263K |
| Net loss before income taxes | -$5.5M+27.8% | -$7.6M+5.1% | -$8.0M+26.5% | -$10.9M |
| Provision (benefit) for income taxes | -$150K-207.3% | $140K+404.6% | $28K+867.5% | $3K |
| Net loss from continuing operations | -$5.3M+31.1% | -$7.7M | — | — |
| Loss on disposal of NTI (Note 4) | -$1.5M | — | — | — |
| Loss on discontinued operations of NTI (Note 4) | -$16.5M-983.1% | -$1.5M | — | — |
| Net loss | -$23.3M-151.9% | -$9.3M-15.2% | -$8.0M+26.2% | -$10.9M |
| Preferred stock dividends and deemed dividends | -$1.8M-621.0% | -$251K | — | — |
| Net loss attributable to common shareholders | -$25.1M-164.3% | -$9.5M-18.4% | -$8.0M | — |
| Basic | $117K+4557.2% | $3K-97.9% | $119K-80.3% | $606K |
| Diluted | $117K+4557.2% | $3K-97.9% | $119K-80.3% | $606K |
| Clinic Revenue [Member] | ||||
| Product [Member] | ||||
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
INVO Fertility reported FY2025 revenue of $6.8M, up 5% YoY, with improved net loss of $(5.3)M versus $(7.7)M, strengthened balance sheet, and fourth clinic acquisition completed
“We believe the business has now moved beyond stabilization and into a higher-growth phase.”
No Form 4 transactions on record.
Informational purposes only, not investment advice.